Key result
Intensive glucose control provides no cognitive benefit in T1DM and increases mortality in T2DM.
Why the study?
Few reports have assessed the impact of intensive glucose control on cognitive function in patients with diabetes.
Does intensive glucose control improve cognitive function in patients with type 1 or type 2 diabetes compared to standard therapy?
Meta-Analysis
Does intensive glucose control improve cognitive function in patients with type 1 or type 2 diabetes compared to standard therapy?
Intensive glucose control does not provide overall cognitive benefit in diabetes and is associated with worse memory/attention and higher mortality in type 2 diabetics.
Diabetes mellitus is associated with cognitive decline and impaired performance in cognitive function tests among type 1 and type 2 diabetics. Even though the use of tight glucose control has been limited by a reported higher mortality, few reports have assessed the impact of treatment intensity on cognitive function. We conducted a meta-analysis to evaluate if an intensive glucose control in diabetes improves cognitive function, in comparison to standard therapy. We included 7 studies that included type 1 or type 2 diabetics and used standardized tests to evaluate various cognitive function domains. Standardized mean differences (SMDs) were calculated for each domain. We found that type 1 diabetics get no cognitive benefit from a tight glucose control, whereas type 2 diabetics get some benefit on processing speed and executive domains but had worse performances in the memory and attention domains, along with a higher incidence of mortality when using intensive glucose control regimes.
No takes yet. Share an insight, caveat, or question.
Peñaherrera et al. (2015) conducted a meta-analysis in Diabetes mellitus (type 1 and type 2). Intensive glucose control vs. Standard therapy was evaluated on Cognitive function domains. Intensive glucose control provided no cognitive benefit in type 1 diabetics, and mixed cognitive effects with higher mortality in type 2 diabetics compared to standard therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: